Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.
1 report, 1 independent
Updated Oct 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
Morgan Stanley
U.S. investment bank
Related events
- Morgan Stanley, Jefferies, and Citigroup commented on Cullen/Frost Bankers, boosting targets and issuing sell/underweight ratings on July 25, 2026.
- Morgan Stanley and Jefferies Financial Group adjusted price targets and ratings for Lincoln National Corporation.
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
- Multiple financial firms, including Morgan Stanley and TD Cowen, updated price targets and ratings for various institutions on October 31, 2026.
- Truist Financial, Leerink partners, and Morgan Stanley have raised price targets and weighed in on Incyte stock.